Danaher 2026: Revenue $6.55B, EPS $1.75— 10-Q Summary

Danaher reported Q3 2026 revenue of $6.55B, up 8.3% YoY, and EPS of $1.75, up 37.8% YoY. Growth driven by core sales and acquisitions, including Masimo, which added $1.5B in revenue. Net income rose 36% to $1.24B. Geographic performance varied, with high-growth markets like China leading.

Original reporting
Published Oct 21, 2026, 10:11 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 10:23 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Danaher 2026: Revenue $6.55B, EPS $1.75— 10-Q Summary — source image
Decision brief

The 30-second read

$DHRBullishMed
01

Why it matters

The earnings beat and acquisition contribution suggest a bullish short‑term outlook for DHR.

02

Market read

First‑report earnings data for a large‑cap industrial leader, likely to influence sector sentiment and short‑term price action.

03

What to watch

Supply-chain delays and higher logistics costs could pressure margins despite top-line growth.

Relevance 8/10Novelty 8/10Timing: after-market today

Background

Danaher released its Q3 2026 10‑Q, highlighting revenue growth, acquisition impact, and mixed geographic performance.

Company-level read

Ticker impact

$DHRBullishHigh confidence
Context

Danaher posted Q3 2026 revenue of $6.55B and EPS $1.75, beating prior-year figures and highlighting acquisition contributions.

Expected impact

likely upward pressure as investors price in earnings beat and acquisition synergies

Evidence & confidence

Revenue and EPS both exceeded prior-year levels; acquisition of Masimo added $1.5B revenue, indicating growth momentum.

Market effects

Positive earnings may lift the broader industrial and life-sciences equipment sector.

Strong performance in China and Western Europe could boost regional market sentiment.

Danaher's results reinforce confidence in large-cap industrial conglomerates globally.

Counterpoint

If acquisition integration costs rise, the earnings beat may be short-lived.

Key entities

  • Danaher Corp.

    Industrial and life‑sciences conglomerate reporting Q3 2026 results.

  • Masimo Corp.

    Acquired by Danaher, adding $1.5B revenue to the diagnostics segment.

Related articles

$DHRMed

Beckman Coulter receives FDA clearance for bacterial infection test

Beckman Coulter Diagnostics, part of Danaher Corporation, received FDA clearance for the Access MeMed BV assay, a blood test distinguishing bacterial from viral infections in patients aged 90 days and older. The test runs on the company's DxI 9000 and Access 2 immunoassay analyzers, providing results in 15 minutes. Developed with MeMed, the test measures immune-response proteins to generate a bacterial infection likelihood score.

$DHRMed

UBS reiterates Danaher stock Buy rating on Q3 results and outlook

UBS reiterated a Buy rating on Danaher (DHR) with a $260 price target, citing Q3 results and outlook. The stock, near its 52-week high, has risen 27.6% in six months. Danaher reported Q3 core revenue growth of 2.5% to 3.0% and adjusted earnings of $2.11 per share, exceeding expectations. Stifel also raised its price target to $260, noting strong nonrespiratory growth.